News
28 August 2025
Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan),
Read more...28 August 2025
Sandoz the global leader in generic and biosimilar medicines, today announced the launch of generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg and 20 mg. Rivaroxaban - 1 A Pharma® offers patients
Read more...MannKind Corporation and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.
Read more...26 August 2025
Genentech, a member of the Roche Group today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility
Read more...22 August 2025
Crinetics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone
Read more...22 August 2025
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE)
Read more...21 August 2025
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling
Read more...Madrigal Pharmaceuticals, Inc, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the European Commission (EC)
Read more...Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany
Read more...Boehringer Ingelheim and Palatin Technologies, Inc, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system,
Read more...
